Galantamine Executive Function in Parkinson's Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00211588 |
Recruitment Status
: Unknown
Verified May 2007 by Memorial Hospital of Rhode Island.
Recruitment status was: Active, not recruiting
First Posted
: September 21, 2005
Last Update Posted
: May 7, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Parkinson's Disease | Drug: galantamine | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 90 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Prevention |
Official Title: | Investigator Initiated Study: Galantamine CR Potential Enhancement of Attentional and Executive Function in Non-Demented Patients With Parkinson's Disease |
Study Start Date : | June 2004 |
Estimated Study Completion Date : | May 2007 |

- Improvement on cognitive measures [ Time Frame: 16 weeks ]
- No worsening of PD symptoms [ Time Frame: 16 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years to 85 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Idiopathic Parkinson's Disease
Exclusion Criteria:
- dementia, depression, cardiac disease, gastrointestinal disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00211588
United States, Rhode Island | |
Memorial Hospital of RI | |
Pawtucket, Rhode Island, United States, 02860 |
Principal Investigator: | Joseph H Friedman, M.D. | NeuroHealth | |
Study Director: | Janet Grace, Ph.D. | Memorial Hospital of RI |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00211588 History of Changes |
Other Study ID Numbers: |
GAL-EMR-4022 |
First Posted: | September 21, 2005 Key Record Dates |
Last Update Posted: | May 7, 2007 |
Last Verified: | May 2007 |
Keywords provided by Memorial Hospital of Rhode Island:
cognition |
Additional relevant MeSH terms:
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases Galantamine Cholinesterase Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Cholinergic Agents Neurotransmitter Agents Physiological Effects of Drugs Parasympathomimetics Autonomic Agents Peripheral Nervous System Agents Nootropic Agents |